Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles - 11/07/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 8 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | EGFR targeted therapy is available for the treatment of advanced NSCLC. |
• | LPNs can combine the beneficial properties of lipid and polymeric NPs. |
• | EGFR-targeted LPNs for delivery of DTX and RSV is a promising strategy for treatment of NSCLC. |
Abstract |
Special targeted therapy like endothelial growth factor receptor (EGFR) targeted therapy is available for the treatment of advanced non-small cell lung cancer (NSCLC). Biodegradable core-shell lipid-polymer hybrid nanoparticles (LPNs) can combine the beneficial properties of lipid and polymeric NPs for controlled drug delivery. In the present study, epidermal growth factor (EGF) conjugated LPNs were fabricated to co-deliver docetaxel (DTX) and resveratrol (RSV). In vitro and in vivo studies demonstrated that EGF DTX/RSV LPNs have significant synergistic effects, best tumor inhibition ability and the lowest systemic toxicity. The results indicate that EGF DTX/RSV LPNs may be a promising strategy for treatment of NSCLC.
Le texte complet de cet article est disponible en PDF.Keywords : Non-small cell lung cancer, Endothelial growth factor receptor, Drug resistance, Reactive oxygen species, Resveratrol, Docetaxel
Plan
Vol 105
P. 18-26 - septembre 2018 Retour au numéro
Article précédent
- SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma
- Chao Yu, Bo Zhang, Ya-Li Li, Xiao-Rui Yu
- Taxifolin binds with LXR (α & β) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway
- Md.Wasimul Haque, Pritha Bose, Mohd. Usman Mohd Siddique, Priyashree Sunita, Antonio Lapenna, Shakti P. Pattanayak
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?